News stories about Amedisys (NASDAQ:AMED) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedisys earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned press coverage about the health services provider an impact score of 45.4061989865362 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Amedisys (AMED) opened at $55.31 on Friday. Amedisys has a one year low of $41.98 and a one year high of $65.91. The firm has a market cap of $1,861.43, a P/E ratio of 26.24, a price-to-earnings-growth ratio of 1.33 and a beta of 0.70. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.16.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. During the same quarter last year, the firm earned $0.36 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. equities research analysts expect that Amedisys will post 2.23 EPS for the current fiscal year.

Several brokerages have commented on AMED. Benchmark restated a “hold” rating on shares of Amedisys in a report on Thursday, November 9th. Robert W. Baird reaffirmed a “hold” rating and set a $50.00 target price on shares of Amedisys in a research note on Wednesday, October 4th. Mizuho reaffirmed a “buy” rating and set a $65.00 target price (up previously from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Bank of America began coverage on shares of Amedisys in a research note on Monday, August 21st. They set a “neutral” rating and a $55.00 target price for the company. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $70.00 target price on shares of Amedisys in a research note on Friday, November 10th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $61.00.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with Analyst Ratings Network's FREE daily email newsletter.